Deadline Alert: Class Action Lawsuit Filed Against Applied Therapeutics

Investors who have purchased shares of Applied Therapeutics are facing a deadline to join a class action lawsuit against the company. The lawsuit alleges that Applied Therapeutics made misleading statements regarding the results of its drug trials, which led to inflated stock prices. Investors who suffered losses as a result of these alleged misrepresentations are encouraged to reach out to BFA Law before the deadline passes.

Applied Therapeutics is a biopharmaceutical company focused on developing treatments for rare genetic diseases. The company’s lead drug candidate, AT-007, is being studied as a potential treatment for Galactosemia, a rare metabolic disorder. Applied Therapeutics has conducted clinical trials to evaluate the safety and efficacy of AT-007, with the hope of obtaining regulatory approval for the drug.

However, according to the class action lawsuit, Applied Therapeutics failed to disclose certain information about the results of its drug trials. The lawsuit alleges that the company made false and misleading statements about the efficacy of AT-007, causing investors to believe that the drug was more successful than it actually was. As a result, the company’s stock price was artificially inflated, and investors who purchased shares at these inflated prices suffered significant losses when the truth about the drug trials was revealed.

The deadline for investors to join the class action lawsuit against Applied Therapeutics is approaching, and those who wish to participate are encouraged to contact BFA Law as soon as possible. By joining the lawsuit, investors may be able to recover some of their losses related to their investment in Applied Therapeutics.

Investors who have been affected by the alleged misrepresentations made by Applied Therapeutics should not hesitate to reach out to BFA Law for more information on how to join the class action lawsuit. Time is of the essence, as the deadline for participation is rapidly approaching. By taking action now, investors may be able to recoup some of their losses and hold Applied Therapeutics accountable for any wrongdoing related to its drug trials and the subsequent impact on its stock price.